WO2000062802A3 - Vaccine comprising rsv antigen and cpg oligonucleotide - Google Patents

Vaccine comprising rsv antigen and cpg oligonucleotide Download PDF

Info

Publication number
WO2000062802A3
WO2000062802A3 PCT/EP2000/003516 EP0003516W WO0062802A3 WO 2000062802 A3 WO2000062802 A3 WO 2000062802A3 EP 0003516 W EP0003516 W EP 0003516W WO 0062802 A3 WO0062802 A3 WO 0062802A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
cpg oligonucleotide
rsv antigen
vaccine formulation
rsv
Prior art date
Application number
PCT/EP2000/003516
Other languages
French (fr)
Other versions
WO2000062802A2 (en
Inventor
Marguerite Deschamps
Original Assignee
Smithkline Beecham Biolog
Marguerite Deschamps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9915106.0A external-priority patent/GB9915106D0/en
Application filed by Smithkline Beecham Biolog, Marguerite Deschamps filed Critical Smithkline Beecham Biolog
Priority to CA002370708A priority Critical patent/CA2370708A1/en
Priority to AU45525/00A priority patent/AU762857B2/en
Priority to EP00926986A priority patent/EP1171158A2/en
Publication of WO2000062802A2 publication Critical patent/WO2000062802A2/en
Publication of WO2000062802A3 publication Critical patent/WO2000062802A3/en
Priority to HK02104795.7A priority patent/HK1045099A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a vaccine formulation comprising a Respiratory Syncytial Virus (RSV) antigen and an immunostimulatory CpG oligonucleotide, to methods of preparing the vaccine formulation and to its use in medicine. Further antigens may be included to provide new combination vaccines for administration to children, to adults and to the elderly.
PCT/EP2000/003516 1999-04-20 2000-04-17 Vaccine comprising rsv antigen and cpg oligonucleotide WO2000062802A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002370708A CA2370708A1 (en) 1999-04-20 2000-04-17 Vaccine comprising rsv antigen and cpg oligonucleotide
AU45525/00A AU762857B2 (en) 1999-04-20 2000-04-17 Vaccine
EP00926986A EP1171158A2 (en) 1999-04-20 2000-04-17 Vaccine comprising rsv antigen and cpg oligonucleotide
HK02104795.7A HK1045099A1 (en) 1999-04-20 2002-06-27 Vaccine comprising rsv antigen and cpg oligonucleotide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9909077.1 1999-04-20
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9915106.0A GB9915106D0 (en) 1999-06-28 1999-06-28 Vaccine
GB9915106.0 1999-06-28

Publications (2)

Publication Number Publication Date
WO2000062802A2 WO2000062802A2 (en) 2000-10-26
WO2000062802A3 true WO2000062802A3 (en) 2001-01-11

Family

ID=26315443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003516 WO2000062802A2 (en) 1999-04-20 2000-04-17 Vaccine comprising rsv antigen and cpg oligonucleotide

Country Status (7)

Country Link
EP (1) EP1171158A2 (en)
AR (1) AR023534A1 (en)
AU (1) AU762857B2 (en)
CA (1) CA2370708A1 (en)
CO (1) CO5300406A1 (en)
HK (1) HK1045099A1 (en)
WO (1) WO2000062802A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
AU2001285421A1 (en) * 2000-08-10 2002-02-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine against rsv
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110052237A (en) * 2019-04-19 2019-07-26 贺州学院 A kind of preparation method of porous powdered whiting adsorbent material
JP2023515908A (en) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング CpG-adjuvanted SARS-CoV-2 virus vaccine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1270918A (en) * 1969-11-14 1972-04-19 Merck & Co Inc Preparation of multivalent vaccines
WO1998018819A1 (en) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification of respiratory syncytial virus antigens
WO1998018810A1 (en) * 1996-10-30 1998-05-07 The University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US5837250A (en) * 1994-06-16 1998-11-17 Connaught Laboratories Limited Adjuvant compositions
WO1999033488A2 (en) * 1997-12-24 1999-07-08 Smithkline Beecham Biologicals S.A. Adjuvanted vaccine formulation
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1270918A (en) * 1969-11-14 1972-04-19 Merck & Co Inc Preparation of multivalent vaccines
US5837250A (en) * 1994-06-16 1998-11-17 Connaught Laboratories Limited Adjuvant compositions
WO1998018819A1 (en) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification of respiratory syncytial virus antigens
WO1998018810A1 (en) * 1996-10-30 1998-05-07 The University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1999033488A2 (en) * 1997-12-24 1999-07-08 Smithkline Beecham Biologicals S.A. Adjuvanted vaccine formulation
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLETCHER T J ET AL: "Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease.", BMJ, vol. 314, no. 7095, 1997, pages 1663 - 1665, XP000952814 *
GIEBINK G SCOTT: "Immunology: Promise of new vaccines.", PEDIATRIC INFECTIOUS DISEASE JOURNAL, vol. 13, no. 11, 1994, pages 1064 - 1068, XP000952829, ISSN: 0891-3668 *

Also Published As

Publication number Publication date
AR023534A1 (en) 2002-09-04
AU4552500A (en) 2000-11-02
HK1045099A1 (en) 2002-11-15
WO2000062802A2 (en) 2000-10-26
CO5300406A1 (en) 2003-07-31
EP1171158A2 (en) 2002-01-16
AU762857B2 (en) 2003-07-10
CA2370708A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
EP1878424A3 (en) Novel vaccine
WO2002028426A8 (en) Split enveloped virus preparation
WO2001060402A3 (en) Proteosome influenza vaccine
HUP0402067A2 (en) Vaccines
DE60012042D1 (en) ENTEPNEUMOVIRUS AND APPROPRIATE VACCINE
WO2002087494A3 (en) Novel vaccine
EP2066332A4 (en) Flu vaccine admixture of mannan and flu antigen
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
WO2000035481A3 (en) Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
GB9722682D0 (en) Pharmaceutical products
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
WO2003059385A3 (en) Hiv vaccine and method of use
WO2001095934A3 (en) The use of plant oil-bodies in vaccine delivery systems
NO951982D0 (en) Mucosal delivery of pneumococcal antigens
AU5529599A (en) Vaccine compositions using antigens encapsulated within alginate microspheres for oral administration and preparation process thereof
WO2003032917A3 (en) Hookworm vaccine
WO2003050135A3 (en) Use a parapox b2l protein to modify immune responses to administered antigens
MY127452A (en) Vaccines.
WO2002070004A3 (en) Papillomavirus vaccines
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2370708

Country of ref document: CA

Ref country code: CA

Ref document number: 2370708

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 45525/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000926986

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000926986

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10031002

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 45525/00

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000926986

Country of ref document: EP